These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Palliative chemotherapy with 5 FU and CPM in cancer of the prostate with bone metastases resistant to oestrogens. A clinical trial (author's transl)]. Kuss R; Khoury S; Richard F; Fourcade R; Frantz P; Capelle JP J Urol Nephrol (Paris); 1979; 85(10-11):649-55. PubMed ID: 94108 [TBL] [Abstract][Full Text] [Related]
3. [Cytostatic therapy of prostatic carcinoma. Current status and personal results]. Nagel R; Leistenschneider W Urologe A; 1983 Sep; 22 Suppl():304-9. PubMed ID: 6356555 [TBL] [Abstract][Full Text] [Related]
4. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628 [TBL] [Abstract][Full Text] [Related]
5. [Estrogen-resistant prostatic cancer with bone metastases: palliative chemotherapy with 5-fluorouracil and cyclophosphamide]. Küss R; Khoury S; Richard F; Fourcade R; Frantz P; Capelle JP Nouv Presse Med; 1978 Aug 26-Sep 2; 7(28):2478-9. PubMed ID: 80785 [No Abstract] [Full Text] [Related]
6. Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate. Edsmyr F; Esposti PL; Andersson L Scand J Urol Nephrol Suppl; 1980; 55():139-42. PubMed ID: 6938017 [TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy of advanced prostate cancer]. Murphy GP Vopr Onkol; 1977; 23(12):26-38. PubMed ID: 146305 [No Abstract] [Full Text] [Related]
8. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Eagan RT; Hahn RG; Myers RP Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515 [No Abstract] [Full Text] [Related]
10. Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate? Datta SN; Thomas K; Matthews PN J Urol; 1997 Jul; 158(1):175-7. PubMed ID: 9186348 [TBL] [Abstract][Full Text] [Related]
11. Inverse relationship between serum cholinesterase activity and the administration of cyclophosphamide: an index of cyclophosphamide therapy. Imai H; Kodama T; Yasuda T; Nakamoto Y; Miura AB Nephrol Dial Transplant; 1994; 9(9):1240-9. PubMed ID: 7816283 [TBL] [Abstract][Full Text] [Related]
12. Successful treatment of poor prognostic patients with advanced prostatic carcinoma with the association of diethylstilbestrol and cyclophosphamide. Germá Lluch JR; Marcuello Gaspar E; de Andrés Basauri L; López Pousa A; López López JJ Rev Esp Oncol; 1982; 29(2):317-24. PubMed ID: 7188232 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of a high-dose regimen of cyclophosphamide and prednisolone in advanced non-Hodgkin's lymphoma of favorable histologic type. Bell R; Gallagher CJ; Ford J; Malpas JS; Lister TA Cancer Treat Rep; 1982 Feb; 66(2):377-80. PubMed ID: 7055819 [TBL] [Abstract][Full Text] [Related]
14. [Hypophysectomy in the advanced stage of carcinoma of the prostate (author's transl)]. Klosterhalfen H; Becker H; Lotzin C; Kautzky R Urologe A; 1980 Mar; 19(2):85-8. PubMed ID: 6157241 [TBL] [Abstract][Full Text] [Related]
15. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Glode LM; Barqawi A; Crighton F; Crawford ED; Kerbel R Cancer; 2003 Oct; 98(8):1643-8. PubMed ID: 14534880 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of advanced prostatic carcinoma. Lukkarinen O; Lehikoinen K Ann Chir Gynaecol Suppl; 1993; 206():9-13. PubMed ID: 8291878 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875 [TBL] [Abstract][Full Text] [Related]